Company news
COSCIENS Biopharma Inc. news in 2015
COSCIENS Biopharma Inc.'s news releases, calls and decks from 2015, newest first.
Aeterna Zentaris Affirms Fundamental Strength of Business
November 25, 2015
Aeterna Zentaris Confirms No Corporate Developments
November 24, 2015
Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement
November 24, 2015
Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD
November 19, 2015
Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance
November 18, 2015
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
November 16, 2015
Aeterna Zentaris Announces Exercise of Series B Warrants
November 12, 2015
Aeterna Zentaris Urges Shareholders to Vote in Favor of the Share Consolidation and Highlights Support from ISS and Glass Lewis
November 11, 2015
Aeterna Zentaris Reports Third Quarter Financial and Operating Results
November 5, 2015
Aeterna Zentaris Announces Agreement to Exercise Substantially All Remaining Series B Warrants
November 2, 2015
Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation
October 27, 2015
Aeterna Zentaris to Announce Third Quarter 2015 Financial and Operating Results on November 6, 2015
October 23, 2015
Aeterna Zentaris Announces Special Meeting of Shareholders and Mailing of Management Information Circular
October 16, 2015
Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer
October 13, 2015
Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office
October 12, 2015
Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
September 28, 2015
Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment
September 25, 2015
Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
September 24, 2015
Aeterna Zentaris Announces Amendment to Series B Warrants
September 21, 2015
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
September 3, 2015
Aeterna Zentaris Reports Second Quarter Financial and Operating Results
August 13, 2015
Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October
August 11, 2015
Aeterna Zentaris to Announce Second Quarter 2015 Financial and Operating Results on August 13, 2015
August 6, 2015
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th Annual Global Growth Conference in Boston
August 4, 2015
Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development
July 29, 2015
Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology
July 28, 2015
Aeterna Zentaris Commences Promotional Activities for EMD Serono's Saizen® [Somatropin (rDNA origin) for Injection]
July 27, 2015
Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen(TM) in AGHD Meets EMA's Study-Design Expectations
May 26, 2015
Aeterna Zentaris Announces Election of Directors at 2015 Shareholders' Meeting
May 11, 2015
Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results
May 7, 2015
Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.
May 7, 2015
Aeterna Zentaris to Announce First Quarter 2015 Financial and Operating Results on May 7, 2015 and Hold Annual & Special Shareholders Meeting on May 8, 2015
May 1, 2015
Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer
April 27, 2015
Aeterna Zentaris to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference in Toronto
April 23, 2015
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc.
April 23, 2015
Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin
April 16, 2015
Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen(TM) in AGHD Following Successful Meeting with FDA
April 13, 2015
Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina
March 31, 2015
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results
March 17, 2015
Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants
March 11, 2015
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015
March 10, 2015
Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants
March 6, 2015
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
March 5, 2015
Aeterna Zentaris to Present at Roth Conference 2015
March 2, 2015
Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco
January 6, 2015